Posted by Michael Wonder on 31 Mar 2021
Bluestar Genomics receives FDA breakthrough device designation for first-of-its-kind pancreatic cancer screening test
31 March 2021 - Company accelerates commercialisation efforts to address a million at-risk patients’ unmet needs.
Bluestar Genomics announces today it received U.S. FDA breakthrough device designation for its proprietary non-invasive pancreatic cancer detection test in patients with new-onset diabetes.
